Treatment of malignant melanoma with dacarbazin (DTIC-DOME) with special reference to urinary excretion of 5-S-cysteinyldopa
Authors:
- P-E JönssonPJP-E Jönsson
- G. AgrupGAG. Agrup
- E. ArnbjörnssonEAE. Arnbjörnsson
- Lo HafströmLHLo Hafström
- H. RorsmanHRH. Rorsman
Abstract
Patients (17) were given DTIC [dacarbazine], 200 mg/m2 per day in 5 day courses every 4-6 wk. In 4 patients (stage II) treated on an adjuvant basis, tumor recurrence has been verified in 3. Four of the palliatively treated patients were also given DTIC by regional intra-arterial infusion with minimal positive tumor effect and minimal toxicity. 5-S-cysteinyldopa excretion in urine was checked continuously in all patients. Tumor recurrence was revealed in 2 patients given DTIC on an adjuvant basis 3 and 4 mo. before clinical signs of tumor. In the palliatively treated patients, 5-S-cysteinyldopa excretion increased in 5/6 patients judged to have stable disease, before tumor progression was clinically detectable. The use of 5-S-cysteinyldopa examination is a valuable adjunct to the follow-up of the effect of DTIC therapy in melanoma patients.Keywords
This publication has 6 references indexed in Scilit:
- Results with methyl-CCNU and DTIC in metastatic melanomaCancer, 1977
- Comparison of the combination of 1, 3-bis(2-chloroethyl)-l-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-l-triazino) imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanomaCancer, 1975
- Integration of chemotherapy into combined modality therapy of solid tumorsCancer Treatment Reviews, 1974
- Intra-arterial infusion therapy with 5-(3,3-dimeth yl-1-triazeno) imidazole-4-carboxamide (NSC 45388) for malignant melanomaCancer, 1973
- Characteristics of prognosis and response to an imidazole carboxamide in malignant melanomaClinical Pharmacology & Therapeutics, 1971
- Prolonged and Continuous Regional Arterial Infusion Chemotherapy in Patients With MelanomaJAMA, 1969